**Plasmodium falciparum** Uses gC1qR/HABP1/p32 as a Receptor to Bind to Vascular Endothelium and for Platelet-Mediated Clumping

Anup Kumar Biswas1,2, Abdul Hafiz1, Bhaswati Banerjee2, Kwang Sik Kim3, Kasturi Datta2*, Chetan E. Chitnis1*

1 Malaria Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, India, 2 School of Environmental Sciences, Jawaharlal Nehru University, New Delhi, India, 3 Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

The ability of *Plasmodium falciparum*-infected red blood cells (IRBCs) to bind to vascular endothelium, thus enabling sequestration in vital host organs, is an important pathogenic mechanism in malaria. Adhesion of *P. falciparum* IRBCs to platelets, which results in the formation of IRBC clumps, is another cytoadherence phenomenon that is associated with severe disease. Here, we have used in vitro cytoadherence assays to demonstrate, to our knowledge for the first time, that *P. falciparum* IRBCs use the 32-kDa human protein gC1qR/HABP1/p32 as a receptor to bind to human brain microvascular endothelial cells. In addition, we show that *P. falciparum* IRBCs can also bind to gC1qR/HABP1/p32 on platelets to form clumps. Our study has thus identified a novel host receptor that is used for both adhesion to vascular endothelium and platelet-mediated clumping. Given the association of adhesion to vascular endothelium and platelet-mediated clumping with severe disease, adhesion to gC1qR/HABP1/p32 by *P. falciparum* IRBCs may play an important role in malaria pathogenesis.

Citation: Biswas AK, Hafiz A, Banerjee B, Kim KS, Datta K, et al. (2007) *Plasmodium falciparum* uses gC1qR/HABP1/p32 as a receptor to bind to vascular endothelium and for platelet-mediated clumping. PLoS Pathog 3(9): e130. doi:10.1371/journal.ppat.0030130

**Introduction**

Malaria continues to be a major public health problem in many parts of the tropical world, with approximately 500 million malaria cases reported annually that result in 1–2 million deaths every year [1,2]. Deaths from malaria mainly occur in young children living in sub-Saharan Africa and are caused by infection with *P. falciparum*. One of the important virulence mechanisms associated with *P. falciparum* infection is the unique ability of *P. falciparum* trophozoites and schizonts to sequester in the vasculature of diverse host organs [3–7]. Sequestration of *P. falciparum*-infected red blood cells (IRBCs) in the microvasculature of the brain is associated with severe pathological outcome of cerebral malaria [3,5,7]. *P. falciparum* IRBCs can also bind to platelets to form platelet-mediated clumps, a cytoadherence phenomenon that is associated with severe disease [8–10].

Adhesion of IRBCs to vascular endothelium is mediated by interaction of the *P. falciparum* erythrocyte membrane protein-1 (PfEMP-1) family of variant surface antigens with host receptors [11–13]. The endothelial receptors used by *P. falciparum* for adhesion include thrombospondin (TSP) [14], CD36 [15], intercellular adhesion molecule-1 (ICAM-1) [16], platelet/endothelial cell adhesion molecule (PECAM/CD31) [17], vascular cell adhesion molecule-1 (VCAM-1) [18], endothelial leukocyte adhesion molecule-1 (ELAM-1) [19], normal immunoglobulin (IgG) [20], chondroitin sulfate A (CSA) [20,21], and hyaluronic acid (HA) [22]. Expression of ICAM-1 is upregulated on cerebrovascular endothelium [5,23], and *P. falciparum* IRBCs co-localize with ICAM-1 in cerebral vessels of patients who die of cerebral malaria [23], suggesting that adhesion to ICAM-1 plays a key role in cerebral sequestration. Adhesion of *P. falciparum* IRBCs to host vascular endothelium under flow conditions involves three distinct events, namely, margination, rolling, and static arrest/tethering, which may require multiple receptor–ligand interactions [24–26]. Adhesion to endothelial cells under flow requires binding of *P. falciparum* IRBCs to ICAM-1 as well as to CD36 [25]. Expression of ICAM-1 on brain endothelium is upregulated during blood stage *P. falciparum* infection [5,23]. However, the expression of CD36 on brain endothelial cells is minimal [23]. Platelets, which have been shown to accumulate in brain microvasculature of patients who die of cerebral malaria, express CD36 on their surface and may act as bridges for adhesion of *P. falciparum* IRBCs with brain vascular endothelium [27–29]. Alternatively, other as yet unidentified endothelial receptors may play a role in adhesion of *P. falciparum* IRBCs to cerebral capillaries. In case of platelet-mediated clumping, the only receptor identified for binding of IRBCs to platelets thus far is CD36 [9]. However, in previous studies, antibodies to CD36 could not completely...
**Author Summary**

Adhesion of *Plasmodium falciparum*–infected red blood cells (IRBCs) to the endothelium lining the capillaries of vital host organs can obstruct blood circulation and is an important pathogenic mechanism in malaria. Adhesion of *P. falciparum* IRBCs to platelets results in the formation of IRBC clumps that can also obstruct blood flow and is implicated in severe malaria. Here, we have identified a novel cytoadherence receptor that is found on both endothelial cells and platelets. We demonstrate, for the first time to our knowledge, that *P. falciparum* IRBCs use the 32-kDa human protein gC1qR/HABP1/p32 as a receptor to bind to human endothelial cells, including brain microvascular endothelial cells. In addition, we show that *P. falciparum* IRBCs can bind to gC1qR/HABP1/p32 on platelets to form clumps. Our study has thus identified a novel host receptor that is used for both adhesion to vascular endothelium and platelet-mediated clumping. Given the association of these cytoadherence phenomena with severe disease, our study opens the door to investigations on the role of adhesion of *P. falciparum* IRBCs to gC1qR/HABP1/p32 in malaria pathogenesis.

---

**Table 1. Adhesion of *P. falciparum* Field Isolates and Laboratory Strains to gC1qR/HABP1, CD36, and ICAM-1**

| *P. falciparum* | Name | gC1qR/HABP1 | CHO-CD36 | CHO-ICAM |
|----------------|------|-------------|-----------|-----------|
| **Field isolates** | | | | |
| Cal3770 | 70 | 22 | 62 |
| Cal3813 | 0 | 107 | 0 |
| Cal3875 | 0 | 20 | 52 |
| Raj68 | 0 | 52 | 0 |
| Raj86 | 160 | 126 | 5 |
| Raj116 | 0 | 7 | 0 |
| JDP8 | 0 | 0 | 332 |
| IGH-CR14 | 290 | 61 | 15 |
| **Laboratory strains** | | | | |
| A4 | 20 | 95 | 16 |
| ITG-ICAM | 0 | 85 | 111 |
| 3D7 | 40 | 47 | 0 |

---

*Specific binding of *P. falciparum* IRBCs to gC1qR/HABP1 coated on plastic Petri plates. Number of IRBCs bound per mm² is shown. Data represent average of two independent experiments. Each assay was performed in duplicate. Standard error was less than 10% in each case.*

---

**Results**

**Binding of *P. falciparum* Laboratory Strains and Field Isolates to Endothelial Receptors gC1qR/HABP1, CD36, and ICAM-1**

Recombinant human gC1qR/HABP1 was expressed in *E. coli* and purified to homogeneity (Figure S1). Recombinant gC1qR/HABP1 has the expected mobility on SDS-PAGE and has a purity of greater than 98%. Analysis by gel permeation chromatography reveals that the majority of gC1qR/HABP1 is trimeric, as predicted by the crystal structure ([41], Figure S1). Dimers and trimers of gC1qR/HABP1 purified by gel permeation chromatography migrate with the expected mobility for gC1qR/HABP1 monomers by SDS-PAGE (Figure S1). Recombinant gC1qR/HABP1 binds its known ligands, C1q (Figure S2) and HA (Figure S2), confirming that it is functional. *P. falciparum* laboratory strains as well as field isolates were tested for binding to recombinant gC1qR/HABP1 coated on plastic Petri plates (Table 1; Figure S3) and to CD36 and ICAM-1 expressed on the surface of stably transfected Chinese hamster ovary (CHO) cells (Table 1). Three of the eight *P. falciparum* field isolates tested bind gC1qR/HABP1 (Table 1). Of these, IGH-CR14 shows the most significant binding to gC1qR/HABP1 (Table 1) and was selected for further analysis. *P. falciparum* laboratory strain 3D7, which binds gC1qR/HABP1 (Table 1), was also used for further study. IGH-CR14 binds CD36 and ICAM-1 in addition to gC1qR/HABP1, whereas 3D7 binds CD36 and gC1qR/HABP1 but not ICAM-1 (Table 1). IGH-CR14 binds gC1qR/HABP1 monomers and trimers at similar levels (Figure S3). Soluble C1q blocks the binding of IGH-CR14 to gC1qR/HABP1, suggesting that binding sites on gC1qR/HABP1 used by IRBCs and C1q may be overlapping (Figure S4). HA has no effect on binding of IGH-CR14 to gC1qR/HABP1 (Figure S4).

Polymerase chain reaction–based analysis of two polymorphic antigens, MSP-1 and MSP-2, using methods described previously [42] confirmed that both IGH-CR14 and 3D7 contain single distinct genotypes (unpublished data). However, both IGH-CR14 and 3D7 may contain multiple variants with distinct binding phenotypes as a result of antigenic variation. In order to test if *P. falciparum* IRBCs, which bind gC1qR/HABP1, can also bind other receptors like CD36 or ICAM-1, we selected IGH-CR14 and 3D7 for binding to gC1qR/HABP1, separated binders (IGH-CR14+ and 3D7+) from non-binders (IGH-CR14− and 3D7−), and tested them in binding assays. As expected, IGH-CR14+ and 3D7+ show increased binding to gC1qR/HABP1, whereas IGH-CR14− and 3D7− display reduced binding to gC1qR/HABP1 compared to IGH-CR14 and 3D7, respectively (Table 2). The gC1qR/HABP1 disrupt clumps formed by some *P. falciparum* field isolates [9], suggesting that alternative host receptors may participate in platelet-mediated clumping.

Here, we report the identification of the 32-kDa human protein gC1qR/HABP1/p32 (referred to below as gC1qR/HABP1 for brevity) as a novel host receptor for cytoadherence by *P. falciparum*. gC1qR/HABP1 is a ubiquitously expressed membrane protein that was initially shown to bind to the globular “head” of complement component C1q [30] as well as to HA [31]. This receptor appears to bind to diverse ligands and has multiple functions [32,33]. It is expressed on diverse cell types, including endothelial cells [34], platelets [35], and dendritic cells [36], and is used as a cell surface receptor by microbial pathogens for pathogenic processes such as host cell entry [37,38] and suppression of immune function [39,40]. Given its localization on endothelial cells and platelets, we hypothesized that gC1qR/HABP1 may serve as a cytoadherence receptor for *P. falciparum*.

Here, we demonstrate that gC1qR/HABP1 is expressed on human brain microvascular endothelial cells (HBMECs) and can be used by *P. falciparum* as a receptor for cytoadherence. In addition, we show that *P. falciparum* IRBCs can bind gC1qR/HABP1 on platelets to form platelet-mediated IRBC clumps. Given the association of both of these cytoadherence phenotypes with severe malaria, this study identifies a novel host receptor that may play an important role in malaria pathogenesis.
HABP1 binders, IGH-CR14+ and 3D7+, do not bind ICAM-1 or CD36, whereas IGH-CR14− retains binding to ICAM-1 and CD36, and 3D7− retains binding to CD36 (Table 2). These findings indicate that binding of *P. falciparum* IGH-CR14 and 3D7 to gC1qR/HABP1 is not linked to binding to ICAM-1 or CD36.

### Expression of gC1qR on Human Endothelial Cells

We have used mouse serum raised against recombinant gC1qR/HABP1 to detect gC1qR/HABP1 on the surface of human umbilical vein endothelial cells (HUVECs), immortalized HBMECs, and primary brain microvascular cells (PBMECs) by flow cytometry. Anti-gC1qR/HABP1 mouse serum recognizes a single band of the expected size (32 kDa) in whole cell lysates as well as in membrane preparations of HUVECs by western blotting (Figure S5). Moreover, anti-gC1qR/HABP1 mouse serum detects gC1qR/HABP1 on the surface of HUVECs, HBMECs, and PBMECs by flow cytometry (Table S1). Unlike ICAM-1, surface expression of gC1qR/HABP1 is not significantly upregulated on the surface of HUVECs, HBMECs, and PBMECs following treatment with TNF-α (Table S1). CD36 is not detected on the surface of HUVECs, HBMECs, and PBMECs before or after treatment with TNF-α (Table S1).

### *P. falciparum* IGH-CR14+ and 3D7+ Use gC1qR/HABP1 as a Receptor to Bind Endothelial Cells

In order to explore if *P. falciparum* IRBCs use gC1qR/HABP1 to bind endothelial cells, we tested IGH-CR14 and 3D7 for binding to HUVECs and HBMECs. We also tested whether selection of IGH-CR14 and 3D7 for binding to gC1qR/HABP1 results in enhanced binding to endothelial cells. IGH-CR14+ and 3D7+ show increased binding to both gC1qR/HABP1 and HUVECs compared to IGH-CR14 and 3D7+ (Table 2). The association of enhanced binding to gC1qR/HABP1 and HUVECs (Table 2) suggested that IGH-CR14+ and 3D7+ use gC1qR/HABP1 as a cell surface receptor to bind to HUVECs.

In order to confirm that binding of IGH-CR14+ and 3D7+ to HUVECs was mediated by gC1qR/HABP1, we tested whether soluble gC1qR/HABP1, as well as anti-gC1qR/HABP1 mouse serum, can inhibit binding of IGH-CR14+ and 3D7+ to HUVECs. Soluble gC1qR/HABP1 blocks the binding of both IGH-CR14+ and 3D7+ to HUVECs in a dose-dependent manner, whereas bovine serum albumin (BSA) and recombinant ICAM1-Fc have no effect on binding (Figure 1). Anti-gC1qR/HABP1 mouse serum also blocks binding of both IGH-CR14+ and 3D7+ to HUVECs, whereas pre-immune mouse serum and antibodies directed against ICAM-1 or CD36 have no effect on binding (Figure 1). These findings demonstrated that binding of IGH-CR14+ and 3D7+ to HUVECs is mediated by gC1qR/HABP1.

The gC1qR/HABP1 binder IGH-CR14+ also shows increased binding to HBMECs compared to IGH-CR14 and IGH-CR14− (Table 2). Binding of IGH-CR14+ to HBMECs is inhibited by soluble gC1qR/HABP1 but not by ICAM1-Fc or CD36-Fc (Figure 2). Binding of IGH-CR14+ to HBMECs is also inhibited by anti-gC1qR/HABP1 mouse serum but not by pre-immune mouse serum or monoclonal antibodies against ICAM-1 and CD36 (Figure 2). These findings demonstrate that IGH-CR14+ uses gC1qR/HABP1 as a receptor to bind to HBMECs.

### *P. falciparum* IGH-CR14+ and 3D7+ Use gC1qR/HABP1 as a Receptor for Platelet-Mediated Clumping of IRBCs

Mouse serum raised against gC1qR/HABP1 was used to detect expression of gC1qR/HABP1 on the surface of platelets by flow cytometry. P-selectin (CD62) was used as a marker for platelet activation. Whereas gC1qR/HABP1 is detected on the surface of both resting and activated platelets, P-selectin is only expressed on the surface of activated platelets (Table S2). Given the presence of gC1qR/HABP1 on the surface of platelets, we examined whether *P. falciparum* could use gC1qR/HABP1 as a receptor for platelet-mediated IRBC clumping. IGH-CR14, IGH-CR14+, and IGH-CR14− were tested for formation of clumps in the presence of platelet-rich plasma (PRP) and platelet-poor plasma (PPP). All three parasites form clumps in the presence of PRP, whereas no clumps are seen in the presence of PPP (Figure 3). Similarly, 3D7, 3D7+, and 3D7− form clumps in the presence of PRP (Figure 3). The *P. falciparum* isolate JDP8, which binds ICAM-1 and does not bind gC1qR/HABP1 or CD36, does not form clumps in PRP or PPP. IGH-CR14, IGH-CR14+, and 3D7− bind CD36 (Table 2), which is a known receptor for platelet-mediated clumping. IGH-CR14+ and 3D7+ do not bind CD36, but bind gC1qR/HABP1 (Table 2). Analysis of clumps formed by IGH-CR14+ using scanning and transmission electron microscopy confirmed the presence of platelets in the clumps (Figure 3), suggesting that IGH-CR14+ IRBCs use gC1qR/HABP1 as a receptor to form platelet-mediated clumps. In order to confirm the identity of the receptor used by IGH-CR14+ and 3D7+ for platelet-mediated clumping we tested the ability of soluble gC1qR/HABP1 and CD36-Fc, as well as antibodies directed against gC1qR/HABP1 and CD36, to inhibit clumping. Both CD36-Fc and anti-CD36 monoclonal antibodies block the clumping of IGH-CR14, IGH-CR14−, 3D7, and 3D7− (Figures 4 and 5). Soluble gC1qR/HABP1 was not able to inhibit clumping.

### Table 2. Adhesion of *P. falciparum* Isolates to gC1qR/HABP1, CD36, and ICAM-1, and Endothelial Cell Lines HUVEC and HBMEC

| Isolate      | CHO-CD36 | CHO-ICAM1 | HUVEC | HBMEC |
|--------------|----------|-----------|-------|-------|
| IGH-CR14     | 290      | 61        | 15    | 103   |
| IGH-CR14+    | 1720     | 0         | 0     | 478   |
| IGH-CR14−    | 50       | 71        | 19    | 66    |
| 3D7          | 40       | 47        | 0     | 18    |
| 3D7+         | 1790     | 8         | 0     | 202   |
| 3D7−         | 0        | 46        | 0     | 6     |

*P. falciparum* field isolate IGH-CR14 and laboratory strain 3D7 were selected three times on plates coated with gC1qR/HABP1 to separate gC1qR/HABP1 binders (IGH-CR14+ and 3D7+) from non-binders (IGH-CR14− and 3D7−). Specific binding of *P. falciparum* IRBCs to gC1qR/HABP1 coated on plastic Petri plates. Number of IRBCs bound per mm² is reported. Data represent average of two independent experiments. Each assay was performed in duplicate in each experiment. Standard error was less than 10% in each case.
HABP1 and anti-gC1qR/HABP1 mouse serum does not inhibit clumping of these parasites (Figures 4 and 5). These findings indicate that IGH-CR14, IGH-CR14+, 3D7, and 3D7+ primarily use CD36 on platelets to form clumps. Conversely, soluble gC1qR/HABP1 and anti-gC1qR/HABP1 mouse serum block clumping of IGH-CR14+ and 3D7+ parasites, whereas CD36-Fc and anti-CD36 monoclonal antibodies do not have any inhibitory effect on clumping of IGH-CR14+ and 3D7+ parasites (Figures 4 and 5). These studies confirm that both IGH-CR14+ and 3D7+ use gC1qR/HABP1 as a receptor for platelet-mediated clumping.

**Discussion**

Adhesion of *P. falciparum* IRBCs to endothelial receptors, which enables sequestration in host organs, and binding to
Platelets, which produce IRBC clumps, are important pathogenic mechanisms in malaria [4–10]. Here, we report the identification of the 32-kDa human protein gC1qR/HABP1 as a novel cytoadherence receptor for adhesion of P. falciparum IRBCs to both endothelial cells and platelets.

gC1qR/HABP1 is synthesized as a 282–amino acid pre-pro protein, which contains a 73–amino acid long N-terminal mitochondrial targeting sequence [43,44]. gC1qR/HABP1 is found in mitochondria and also on the surface of mammalian cells. There are other examples of proteins that have mitochondrial localization sequences and are found in other cellular locations in addition to mitochondria [45]. For example, mitochondrial aspartate aminotransferase (ApsAT) is found in the mitochondria as well as on the plasma membrane of adipocytes, where it is involved in binding and uptake of fatty acids [45]. Another mammalian protein, Slit3, whose homolog in Drosophila is involved in developmental regulation, is predominantly a mitochondrial protein having an N-terminal mitochondrial targeting sequence, but is also shown to be expressed on epithelial cell surfaces [46]. The mechanisms by which these proteins translocate to the cell surface and to the mitochondria are not known. Given the presence of the mitochondrial targeting sequence and absence of a transmembrane domain or consensus glycosphingolipid (GPI)–anchoring signature sequence, the surface localization of gC1qR/HABP1 is intriguing. The localization of gC1qR/HABP1 on the surface of diverse human cells has been demonstrated unequivocally both here and previously [31–34,47,48]. We have demonstrated here that mouse serum raised against recombinant gC1qR/HABP1 specifically reacts with a protein of the expected size for gC1qR/HABP1 (32 kDa) in whole cell lysates as well as in membrane fractions of HUVECs by western blotting (Figure S5). Anti-gC1qR/HABP1 mouse serum detects the presence of gC1qR/HABP1 on the surface of HUVECs, HBMECs, and PBMECs by flow cytometry (Table S1). The observation that gC1qR/HABP1 is expressed on the surface of microvascular endothelial cells suggests the possibility that it may be used as

Figure 3. Platelet-Mediated Clumping of P. falciparum IRBCs
(A) Frequency of platelet-mediated clumping in PRP and PPP. P. falciparum field isolate IGH-CR14, laboratory strain 3D7, and their derivatives, IGH-CR14+ and 3D7+, which bind gC1qR/HABP1, IGH-CR14−, and 3D7−, which bind CD36, and P. falciparum isolate JDP8, which does not bind gC1qR/HABP1 or CD36, were tested for clumping in the presence of PRP and PPP. Parasites were stained with acridine orange and the clumping frequency was determined by scoring the frequency of IRBCs found in clumps. Approximately 500 IRBCs were scored for each parasite. The frequency of clumping in the presence of PRP (grey bars) and PPP (black bars) is shown.
(B) Scanning electron micrograph of platelet-mediated clumps formed by IGH-CR14+. Clumps formed by IGH-CR14+ IRBCs in the presence of PRP were analyzed by scanning electron microscopy. Electron micrograph shows several platelets (marked P), which bridge IRBCs in the clumps.
(C) Transmission electron micrograph of platelet-mediated clumps formed by IGH-CR14+. Clumps formed by IGH-CR14+ IRBCs in the presence of PRP were analyzed by transmission electron microscopy. Only IRBCs are present in the clumps. The IRBCs are closely associated with platelets (P) in the clumps.
doi:10.1371/journal.ppat.0030130.g003
a receptor for cytoadherence by *P. falciparum* IRBCs. Given that the expression profile of the cytoadherence receptors gC1qR/HABP1, ICAM-1, and CD36 on HUVECs, HBMECs, and PBMECs is similar, we used HUVECs and HBMECs for adhesion assays with *P. falciparum* IRBCs.

We have demonstrated that *P. falciparum* laboratory strains as well as field isolates can bind to recombinant gC1qR/HABP1 (Table 1; Figure S3). Selection of *P. falciparum* IGH-CR14 and 3D7 for binding to gC1qR/HABP1 resulted in increased binding of IRBCs to HUVECs and HBMECs (Table 2), suggesting that these parasites use gC1qR/HABP1 to bind to human endothelial cells. Indeed, recombinant gC1qR/HABP1, as well as anti-gC1qR/HABP1 mouse serum, blocked the binding of IGH-CR14+ to HUVECs and HBMECs (Figures 1 and 2), confirming that these parasites use gC1qR/HABP1 as a receptor for adhesion of IRBCs to endothelial cells. The demonstration that *P. falciparum* IRBCs can use gC1qR/HABP1 as a receptor to bind to microvascular endothelial

**Figure 4. Inhibition of Platelet-Mediated Clumping of IRBCs by Soluble gC1qR/HABP1 and CD36-Fc**

Parasite cultures in trophozoite and schizont stages were allowed to form clumps in the presence of PRP. Parasites were stained with acridine orange and the clumping frequency was determined by scoring the frequency of IRBCs found in clumps. Approximately 2,000 to 3,000 IRBCs were scored. Parasite cultures were pre-incubated with recombinant gC1qR/HABP1 or CD36-Fc at different concentrations prior to use in clumping assays to test their ability to inhibit clumping. Clumping frequency in the presence of gC1qR/HABP1 or CD36-Fc is expressed as relative clumping compared to clumping in the presence of PRP alone. Data represent the average (± standard error) of two independent experiments. Each assay was performed in duplicate. (A) IGH-CR14, (B) 3D7, (C) IGH-CR14−, (D) 3D7−, (E) IGH-CR14+, (F) 3D7+.

doi:10.1371/journal.ppat.0030130.g004
cells suggests that adhesion to gC1qR/HABP1 may play a role in parasite sequestration in vivo.

Another distinct cytoadherence phenotype that is associated with severe malaria is platelet-mediated clumping of IRBCs. CD36, which is expressed on both resting and activated platelets, has been identified as a receptor for platelet-mediated clumping [9]. However, in a previous study, clumps formed by some *P. falciparum* field isolates could not be disrupted completely by anti-CD36 antibodies [9], suggesting that other unidentified receptors on platelets might also mediate clumping of IRBCs. Previous studies have suggested that gC1qR/HABP1 is expressed on the surface of activated platelets [35]. Here, we have demonstrated that gC1qR/HABP1 is also expressed on resting platelets (Table S2). Expression of gC1qR/HABP1 on the surface increases upon activation of platelets (Table S2). IGH-CR14+ and 3D7+, which bind to gC1qR/HABP1 but not to CD36, formed clumps in the presence of platelets. Formation of clumps by IGH-CR14+ and 3D7+ was inhibited by soluble gC1qR/HABP1 and anti-gC1qR/HABP1 antibodies (Figures 4 and 5). These observations demonstrate that *P. falciparum* IRBCs can use gC1qR/HABP1 as an alternative receptor to bind to platelets and form clumps.

The parasite ligands that mediate adhesion of IRBCs to gC1qR/HABP1 remain to be identified. Previous studies have demonstrated that the PfEMP-1 family of variant surface antigens encoded by *var* genes mediates interactions with a diverse range of host receptors to enable adhesion to host endothelium and sequestration in host organs [4,6,12,13]. It is likely that PfEMP-1 may also mediate adhesion to gC1qR/HABP1. Identification of *var* genes that are differentially transcribed in gC1qR/HABP1 binding parasites may enable the identification of the PfEMP-1 variant that is responsible for adhesion to gC1qR/HABP1.

In summary, we have shown that *P. falciparum* IRBCs use gC1qR/HABP1 as a receptor to bind vascular endothelium and platelets. The observation that *P. falciparum* can use gC1qR/HABP1 as a receptor to bind HBMECs, a cell line derived from brain microvascular endothelial cells, raises the possibility that adhesion of IRBCs to this novel receptor may be important for sequestration in brain microvasculature and cerebral malaria. The contribution of IRBC adhesion to

Figure 5. Inhibition of Platelet-Mediated Clumping of IRBCs by Mouse Serum Directed against gC1qR/HABP1 and Monoclonal Antibody against CD36

Parasite cultures in trophozoite and schizont stages were allowed to form clumps in the presence of PRP. Parasites were stained with acridine orange and the clumping frequency was determined by scoring the percentage of IRBCs found in clumps. Approximately 2,000 to 3,000 IRBCs were scored. The ability of anti-gC1qR/HABP1 mouse serum (anti-gC1qR/HABP1) or anti-CD36 mouse monoclonal IgM antibody (anti-CD36, clone SM8) to inhibit clump formation was tested by pre-incubating platelets with antibodies prior to use in clumping assays. Pre-immune serum (PIS) from mice immunized with gC1qR/HABP1 and purified mouse IgM were used as controls. Clumping frequency in the presence of anti-gC1qR/HABP1 or anti-CD36 is expressed relative to clumping in the presence of PRP alone. Data represent average (± standard error) of two independent experiments. Each assay was performed in duplicate. (A) IGH-CR14, (B) 3D7, (C) IGH-CR14+ (D) 3D7+, (E) IGH-CR14+ (F) 3D7+.

doi:10.1371/journal.ppat.0030130.g005
gC1qR/HABP1 to platelet-mediated clumping and severe disease also needs to be examined. Comparison of the cytoadherence phenotypes of *P. falciparum* isolates collected from patients with mild and severe malaria may allow us to test whether adhesion to gC1qR/HABP1 is associated with an increased risk of severe malaria.

**Materials and Methods**

**Materials.** All chemicals used in the study were from Sigma (http://www.sigmaaldrich.com/) unless otherwise indicated.

**Parasites.** Indian *P. falciparum* field isolates were collected from *P. falciparum*-infected individuals in Calcutta (Cal5770, Cal3813, Cal5875), Rajasthan (Raj68, Raj96, Raj116), Jagdalpur, Madhya Pradesh (JP68), and Rourkela, Orissa (IGH-CR14), and cryopreserved in the Malaria Parasite Bank at the National Institute of Malaria Research, Delhi, India. *P. falciparum* field isolates and laboratory strains (A4, ITG-ICAM, and 3D7) were cultured in RPMI 1640 (Invitrogen, http://www.invitrogen.com/) supplemented either with 10% heat-inactivated pooled human sera or 5% Alumax I (Invitrogen) using O+- RBCs in an environment containing 5% O2, 5% CO2, and 90% N2. Cultures were synchronized by sorbitol treatment as previously described [49]. To select parasites for binding to gC1qR/HABP1, synchronized *P. falciparum* 3D7 and IGH-CR14 cultures in trophozoite/schizont stage were incubated for 1 h in a bacteriological Petri plates coated with recombinant gC1qR/HABP1 as described below. Adhesion or unbound parasites were collected using a pipette and separated from bound parasites. Both bound and unbound parasites were cultured and subjected to selection for binding to gC1qR/HABP1 two more times to separate binders (3D7- and IGH-CR14-) and non-binders (3D7+ and IGH-CR14+).

**Cell lines.** Glycosaminoglycan biosynthesis-defective mutant Chinese hamster ovary cells (CHO-745) stably transfected to express human CD36 (CHO-CD36) and ICAM-1 (CHO-ICAM-1) on their surface [50] were kindly provided by Arthur Scherf, Institut Pasteur, Paris, France. *P. falciparum* 745 CHO cells were cultured in RPMI 1640 with 3% inactivated fetal bovine serum (FBS). HUVECs were cultured in EBM-2 bullet kit media (Cambrex Biosciences, http://www.cambrex.com/) on gelatin-coated flasks according to instructions provided by the supplier. Immortalized HBMECs were cultured as previously described [51]. PBMECs were cultured in EGM-2 media provided by the supplier (ScienCell Research Laboratories, http://www.scienCellonline.com/).

**Purification and characterization of recombinant human gC1qR/HABP1. A DNA fragment encoding mature human gC1qR/HABP1 (amino acids 74–282) was cloned in pET30b vector (Invitrogen) using the NdeI and BamHI restriction enzyme cloning sites. Recombinant gC1qR/HABP1 was expressed in *E. coli* BL21(DE3) by induction with IPTG (1 mM) and purified from supernatants of lysed cells by ammonium sulfate fractionation followed by ion-exchange chromatography using UnoQ (Bio-Rad; http://www.bio-rad.com/) as described previously [39]. Binding of recombinant gC1qR/HABP1 to its ligands, C1q and HABP1, was studied using solid phase trophozoite-schizont stage cultures using methods described earlier [52]. Bound IRBCs were fixed with 2% glutaraldehyde and detected by Giemsa staining. The number of IRBCs and URBCs bound to ~200 CHO cells was scored in duplicate spots in two independent experiments. The number of URBCs bound to CHO-CD36 or CHO-ICAM-1 was subtracted from the number of IRBCs bound to gC1qR/HABP1 to get the number of specific binding events. Fewer than five IRBCs or more per 100 CHO-ICAM1 or CHO-CD36 cell was therefore considered significant.

**Flow cytomtery.** Flow cytometry was used to study the expression of gC1qR/HABP1, ICAM-1, and CD36 in CHO, HBMECs, and PBMECs before and after treatment with TNF-α (eBioscience, http://www.ebioscience.com/) and on the surface of resting and activated platelets.

**Platelet-mediated clumping assay and inhibition of clumping with soluble proteins and sera.** HUVECs and HBMECs were grown on gelatin-coated plates and tested for binding to soluble *P. falciparum* trophozoite-schizont stage cultures using methods described earlier [52]. Bound IRBCs were fixed with 2% glutaraldehyde and detected by Giemsa staining. The number of IRBCs and URBCs bound to ~200 CHO cells was scored in duplicate spots in two independent experiments. The number of URBCs bound to CHO-CD36 or CHO-ICAM-1 was subtracted from the number of IRBCs bound to gC1qR/HABP1 to get the number of specific binding events. Fewer than three URBCs bound to 100 CHO-CD36 or CHO-ICAM1 cells, and fewer than two IRBCs bound to 100 CHO-745 cells in all experiments. Specific binding of ten IRBCs or more per 100 CHO-ICAM1 or CHO-CD36 cell was therefore considered significant.

**Platelet-mediated clumping assay and inhibition of clumping with soluble proteins and sera.** Platelet-mediated clumping assays were performed in the presence of TRP and PPP according to the method described previously [9], IRBCs collected from all cultures were pre-incubated with ICAM1-Fc (R&D Systems, http://www.rndsystems.com/), gC1qR/HABP1, and BSA, or HUVECs were pre-incubated with anti-gC1qR/HABP1 mouse serum or monoclonal antibodies directed against CD36 (clone SM6, Serotec) and ICAM-1 (clone 15.2, Serotec). Binding in the presence of proteins or serum was expressed as percent of binding in absence of any protein or serum.

**Flow cytomtery.** Flow cytometry was used to study the expression of gC1qR/HABP1, ICAM-1, and CD36 in CHO, HBMECs, and PBMECs before and after treatment with TNF-α (eBioscience, http://www.ebioscience.com/) and on the surface of resting and activated platelets.

**Platelet-mediated clumping assay and inhibition of clumping with soluble proteins and sera.** HUVECs and HBMECs were grown on gelatin-coated plates and tested for binding to soluble *P. falciparum* trophozoite-schizont stage cultures using methods described earlier [52]. Bound IRBCs were fixed with 2% glutaraldehyde and detected by Giemsa staining. The number of IRBCs and URBCs bound to ~200 CHO cells was scored in duplicate spots in two independent experiments. The number of URBCs bound to CHO-CD36 or CHO-ICAM-1 was subtracted from the number of IRBCs bound to gC1qR/HABP1 to get the number of specific binding events. Fewer than three URBCs bound to 100 CHO-CD36 or CHO-ICAM1 cells, and fewer than two IRBCs bound to 100 CHO-745 cells in all experiments. Specific binding of ten IRBCs or more per 100 CHO-ICAM1 or CHO-CD36 cell was therefore considered significant.

**Flow cytomtery.** Flow cytometry was used to study the expression of gC1qR/HABP1, ICAM-1, and CD36 in CHO, HBMECs, and PBMECs before and after treatment with TNF-α (eBioscience, http://www.ebioscience.com/) and on the surface of resting and activated platelets.

**Platelet-mediated clumping assay and inhibition of clumping with soluble proteins and sera.** HUVECs and HBMECs were grown on gelatin-coated plates and tested for binding to soluble *P. falciparum* trophozoite-schizont stage cultures using methods described earlier [52]. Bound IRBCs were fixed with 2% glutaraldehyde and detected by Giemsa staining. The number of IRBCs and URBCs bound to ~200 CHO cells was scored in duplicate spots in two independent experiments. The number of URBCs bound to CHO-CD36 or CHO-ICAM-1 was subtracted from the number of IRBCs bound to gC1qR/HABP1 to get the number of specific binding events. Fewer than three URBCs bound to 100 CHO-CD36 or CHO-ICAM1 cells, and fewer than two IRBCs bound to 100 CHO-745 cells in all experiments. Specific binding of ten IRBCs or more per 100 CHO-ICAM1 or CHO-CD36 cell was therefore considered significant.

**Flow cytomtery.** Flow cytometry was used to study the expression of gC1qR/HABP1, ICAM-1, and CD36 in CHO, HBMECs, and PBMECs before and after treatment with TNF-α (eBioscience, http://www.ebioscience.com/) and on the surface of resting and activated platelets.

**Platelet-mediated clumping assay and inhibition of clumping with soluble proteins and sera.** HUVECs and HBMECs were grown on gelatin-coated plates and tested for binding to soluble *P. falciparum* trophozoite-schizont stage cultures using methods described earlier [52]. Bound IRBCs were fixed with 2% glutaraldehyde and detected by Giemsa staining. The number of IRBCs and URBCs bound to ~200 CHO cells was scored in duplicate spots in two independent experiments. The number of URBCs bound to CHO-CD36 or CHO-ICAM-1 was subtracted from the number of IRBCs bound to gC1qR/HABP1 to get the number of specific binding events. Fewer than three URBCs bound to 100 CHO-CD36 or CHO-ICAM1 cells, and fewer than two IRBCs bound to 100 CHO-745 cells in all experiments. Specific binding of ten IRBCs or more per 100 CHO-ICAM1 or CHO-CD36 cell was therefore considered significant.

**Flow cytomtery.** Flow cytometry was used to study the expression of gC1qR/HABP1, ICAM-1, and CD36 in CHO, HBMECs, and PBMECs before and after treatment with TNF-α (eBioscience, http://www.ebioscience.com/) and on the surface of resting and activated platelets.
incubation with parasite cultures to test their ability to block clumping.

**Electron microscopy.** Cells were fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) and processed according to methods described previously [9]. Samples were analyzed on a Morgagni 268D transmission electron microscope (FEI Philips, http://www.fei.com/) and LEO 435 VP scanning electron microscope (Leo Electron Microscopy, http://www.smt.zieiss.com/mits).

**Supporting Information**

Figure S1. Characterization of Recombinant Human gC1qR/HABP1

(A) Purity of recombinant gC1qR/HABP1. Purified gC1qR/HABP1 was analyzed by SDS-PAGE under reducing conditions and detected by Coomassie staining. (B) Immunoblot analysis of recombinant gC1qR/HABP1. Monomers, dimers, and trimers of recombinant gC1qR/HABP1 were purified by gel permeation chromatography and analyzed by SDS-PAGE before and after reduction with β-mercaptoethanol (β-ME). Molecular weights are shown in kDa.

Found at doi:10.1371/journal.ppat.0030130.sg001 (295 KB PDF).

**Figure S2. Functional Characterization of Recombinant gC1qR/HABP1**

(A) Binding of recombinant gC1qR/HABP1 to C1q. Biotinylated recombinant gC1qR/HABP1 specifically binds wells coated with human C1q. (B) Binding of recombinant gC1qR/HABP1 to HA. Biotinylated HA specifically binds to wells coated with recombinant gC1qR/HABP1. Binding to BSA-coated wells was used as control (a and B).

Found at doi:10.1371/journal.ppat.0030130.sg002 (206 KB PDF).

**Figure S3. Binding of P. falciparum IRBCs to Purified gC1qR/HABP1**

(A) Binding of IRBCs to gC1qR/HABP1 coated on plastic Petri plates. Giemsa-stained P. falciparum IRBCs are seen bound to recombinant gC1qR/HABP1 coated on plastic Petri plates. (B) Concentration-dependent binding of IRBCs to gC1qR/HABP1. Binding of P. falciparum IGCR14 IRBCs to gC1qR/HABP1 coated at various concentrations on plastic Petri plates. Data presented are average number of IRBCs bound per mm² (± standard error) scored in duplicate spots in two independent experiments. (C) Binding of IRBCs to monomeric and trimeric gC1qR/HABP1. Binding of P. falciparum IGCR14 to gC1qR/HABP1 monomers and trimers purified by gel permeation chromatography is shown relative to binding to gC1qR/HABP1 containing mixed population (Mix) of monomers, dimers, and trimers. Average relative binding (± standard error) scored in duplicate spots in two independent experiments is reported.

Found at doi:10.1371/journal.ppat.0030130.sg003 (764 KB PDF).

**Figure S4. Binding of P. falciparum IGCR14 to gC1qR/HABP1 in the Presence of C1q and HA**

(A) Binding of P. falciparum IGCR14 to gC1qR/HABP1 and CD36-Fc in the presence of soluble C1q is expressed as relative binding compared to binding in absence of C1q. C1q blocks binding of IGCR14 to gC1qR/HABP1 but does not block binding of IGCR14 to CD36-Fc. (B) Binding of P. falciparum IGH-CR14 to gC1qR/HABP1 in the presence of HA (1 mg/ml) is expressed as relative binding compared to binding in absence of HA. Average relative binding (± standard error) scored in duplicate spots in two independent experiments is reported.

Found at doi:10.1371/journal.ppat.0030130.sg004 (239 KB PDF).

**Figure S5. Detection of gC1qR/HABP1 in HUVEC Cells by Western Blotting**

Western blotting with anti-gC1qR mouse serum (A) and anti-bcl2 rabbit serum (B). HUVEC cells were lysed by multiple cycles of freezing and thawing. Whole cell lysate (L), soluble cytoplasmic fraction (C), and insoluble membrane fraction (M) were separated by SDS-PAGE and probed for presence of gC1qR/HABP1 by western blotting with anti-gC1qR/HABP1 mouse serum. Recombinant gC1qR/HABP1 (1H) was used as a positive control. In a control experiment, rabbit serum raised against the mitochondrial protein, bcl-2, was used to detect any mitochondrial contamination in the membrane fraction. Anti-gC1qR mouse serum detects a protein of the expected size (32 kDa) in all three fractions, including membrane fraction. Anti-bcl2 rabbit serum only detects protein in whole cell lysate and cytosolic fractions.

Found at doi:10.1371/journal.ppat.0030130.sg005 (788 KB PDF).

**Table S1. Detection of gC1qR/HABP1, ICAM-1, and CD36 on HUVECs, HBMECs, and PBMECs Before and After Treatment with TNF-α by Flow Cytometry**

Found at doi:10.1371/journal.ppat.0030130.st001 (37 KB RTF).

**Table S2. Detection of gC1qR/HABP1 and P-Selectin on Resting and Thrombin-Activated Platelets by Flow Cytometry**

Found at doi:10.1371/journal.ppat.0030130.st002 (18 KB RTF).

**Acknowledgments**

We thank David Roberts, University of Oxford, UK, and Arnab Pain, The Wellcome Trust Sanger Institute, Hinxton, UK, for helpful discussions on platelet-mediated clumping assays; N. K. Bhatia and the staff of Rotary Blood Bank, New Delhi, India, for providing human blood for parasite culture and platelet isolation; Taposh K. Das, Tapas Nag, and staff of the Electron Microscopy Facility at the All India Institute of Medical Sciences (AIIMS), New Delhi, India, for help with electron microscopy studies; C. R. Pillai, National Institute of Malaria Research (NIMR), Delhi, India, for providing P. falciparum field isolates Raj68, Raj86, Raj116, and JDP8 from the Malaria Parasite Bank, NIMR, Delhi, India; Bhabhani S. Das, Ispat General Hospital, Rourkela, India, for providing field isolate IGH-CR14; Amitabh Nandi, Calculat School of Tropical Medicine, Calcutta, India, for providing field isolates Cal3770, Cal3813, and Cal3875; Artur Scherf, Institut Pasteur, Paris, France, for providing CHO-745, CHO-CD36, and CHO-ICAM1 cell lines; and Niladri Ganguly, Immunology Group, ICGEB, New Delhi, India, for help with flow cytometry.

**Author contributions.** AKB, AH, KD, and CEC conceived and designed the experiments. AKB, BB, KSK, KD, and CEC contributed reagents/materials/analysis tools. AKB, BB, KS, KD, and CEC performed the experiments. AKB, BB, KSK, KD, and CEC contributed to writing the paper.

**Funding.** This work was supported by an International Senior Research Fellowship Award to CEC from The Wellcome Trust, UK, and a grant to CEC from the European Commission–funded BIOMALPAR Network of Excellence. AKB, AH, and BB performed the experiments. AKB, BB, KS, KD, and CEC contributed. The authors have declared that no competing interests exist.

**References**

1. World Health Organization (1997) World malaria situation in 1994. Part I. Population at risk. Weekly Epidemiol Rec 72: 269-274.
2. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434: 214-217.
3. MacPherson GG, Warrell MJ, White NJ, Looareesuwan S, Warrell DA (1985) Quantitative analysis of the microvascular sequestration of malaria parasites in the human brain. Am J Pathol 119: 385-416.
4. Miller LH, Baruch DI, Marsh K, Dounoubo OK (2002) The pathogenic basis of malaria. Nature 415: 673-679.
5. Pongponratn E, Turner GD, Day NP, Phu NH, Simpson JA, et al. (2003) An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. Am J Trop Med Hyg 69: 345-350.
6. Miller LH, Baruch DI, Marsh K, Dounoubo OK (2002) The pathogenic basis of malaria. Nature 415: 673-679.
9. Pain A, Ferguson DJ, Kai O, Urban BC, Lowe B, et al. (2001) Platelet-mediated clumping of Plasmodium falciparum-infected erythrocytes is a common adhesive phenotype and is associated with severe malaria. Proc Natl Acad Sci U S A 98: 1805–1810.

10. Chotivanich K, Sritab P, Udomsangphet R, Newton P, Spittleska KA, Ruanggeerayuth R, Loaasarueswan S, Roberts DJ, White NJ (2004) Platelet-induced autoglutination of Plasmodium falciparum-infected red blood cells and disease severity in Thailand. J Infect Dis 189: 1052–1055.

11. Leech JH, Barnwell JW, Miller LH, Howard RJ (1984) Identification of a strain-specific malarial antigen exposed on the surface of Plasmodium falciparum-infected erythrocytes. J Exp Med 159: 1567–1575.

12. Biggs BA, Anders RF, Dillon HE, Davern KM, Marti M, et al. (1992) Rapid thrombomodulin binds falciparum malaria parasitized erythrocytes and may mediate cytoadherence. Nature 358: 64–66.

13. Roberts DJ, Craig AG, Berendt AR, Pinches R, Nash G, et al. (1992) Rapid switching to multiple antigenic and adhesive phenotypes in malaria. Nature Medicine 357: 689–692.

14. Roberts DD, Shrewsbury JA, Spitalnik SL, Howard RJ, et al. (1985) Identification of a platelet membrane glycoprotein as a falciparum malaria sequestration receptor. Science 243: 1469–1471.